Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2058

1.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
2.

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005481. doi: 10.1002/14651858.CD005481.pub3. Review.

PMID:
23543540
3.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2016 Dec 10;12:CD004246. doi: 10.1002/14651858.CD004246.pub4. Review.

5.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
6.

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.

Humphreys EH, Chang LW, Harris J.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD006517. doi: 10.1002/14651858.CD006517.pub3. Review.

PMID:
20556768
7.

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.

PMID:
24852077
8.

Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.

Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.

AIDS. 2006 Oct 24;20(16):2099-106.

PMID:
17053356
10.

A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.

Sprenger HG, Langebeek N, Mulder PG, Ten Napel CH, Vriesendorp R, Hoepelman AI, Legrand JC, Koopmans PP, Bravenboer B, Ten Kate RW, Groeneveld P, Bierman W, van der Werf Ts, Gisolf E, Richter C.

HIV Med. 2015 Feb;16(2):122-31. doi: 10.1111/hiv.12186. Epub 2014 Dec 4.

11.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team.

JAMA. 2002 Jul 10;288(2):169-80.

PMID:
12095381
12.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team.

JAMA. 2001 Mar 7;285(9):1155-63. Erratum in: JAMA 2001 Jun 13;285(22):2858.

PMID:
11231744
13.

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.

Curr Med Res Opin. 2004 Jul;20(7):1103-14.

PMID:
15265255
14.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD004246. doi: 10.1002/14651858.CD004246.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 10;12 :CD004246.

PMID:
21154355
15.

A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.

Shey M, Kongnyuy EJ, Shang J, Wiysonge CS.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005481. doi: 10.1002/14651858.CD005481.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD005481.

PMID:
19588374
16.

Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.

Sprenger HG, Langebeek N, Mulder PG, Ten Napel CH, Vriesendorp R, Hoepelman AI, Legrand JC, Koopmans PP, Van Kasteren ME, Bravenboer B, Ten Kate RW, Groeneveld PH, van der Werf TS, Gisolf EH, Richter C.

AIDS Patient Care STDS. 2010 Jun;24(6):361-6. doi: 10.1089/apc.2009.0236.

PMID:
20515418
17.

Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.

Pérez-Elías MJ, Moreno A, Moreno S, López D, Antela A, Casado JL, Dronda F, Gutiérrez C, Quereda C, Navas E, Abraira V, Rodríguez MA.

HIV Clin Trials. 2005 Nov-Dec;6(6):312-9.

PMID:
16452065
18.

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.

Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouédraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouédraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timité-Konan M, Leroy V; MONOD Study Group.

BMC Med. 2017 Apr 24;15(1):85. doi: 10.1186/s12916-017-0842-4.

19.

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.

Wolbers M, Opravil M, von Wyl V, Hirschel B, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Battegay M, Yerly S, Günthard H, Bucher HC; Swiss HIV Cohort Study.

AIDS. 2007 Oct 18;21(16):2201-7.

PMID:
18090047
20.

Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.

Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A.

Antivir Ther. 2003 Feb;8(1):27-35.

PMID:
12713061

Supplemental Content

Support Center